龙灯瑞迪制药WeChat
龙灯瑞迪制药
龙灯瑞迪制药 Language
龙灯瑞迪制药
EN CN
Dacomitinib Tablets
Dacomitinib Tablets
Products Name:Dacomitinib Tablets
Indications: It is used as a monotherapy for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutation.
Strengths: 15mg, 45mg
Drug production license number: Su20160178
Approval Number: Guoyao Zhunzi H20254268, Guoyao Zhunzi H20254267